MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Merck & Co Inc.

Fechado

SetorSaúde

86.47 -0.15

Visão Geral

Variação de preço das ações

24h

Atual

Mín

86.26

Máximo

88.77

Indicadores-chave

By Trading Economics

Rendimento

583M

3.7B

Vendas

-1B

16B

P/E

Médio do Setor

13.318

63.778

EPS

1.72

Rendimento de Dividendos

3.61

Margem de lucro

23.963

Funcionários

73,000

EBITDA

1.3B

6.9B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+29.19% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.61%

2.39%

Próximos Ganhos

24 de abr. de 2025

Próxima data de dividendos

7 de abr. de 2025

Próxima data de ex-dividendo

16 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-26B

227B

Abertura anterior

86.62

Fecho anterior

86.47

Sentimento de Notícias

By Acuity

39%

61%

145 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Merck & Co Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de fev. de 2025, 12:33 UTC

Ganhos

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 de fev. de 2025, 11:57 UTC

Ganhos

Merck 4Q Sales Increase Results in Swing to Profit

24 de mar. de 2025, 05:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 de mar. de 2025, 19:42 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 de mar. de 2025, 10:30 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 de fev. de 2025, 12:00 UTC

Principais Notícias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 de fev. de 2025, 14:48 UTC

Ganhos

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 de fev. de 2025, 11:51 UTC

Ganhos

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 de fev. de 2025, 11:50 UTC

Ganhos

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 de fev. de 2025, 11:31 UTC

Ganhos

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 de fev. de 2025, 11:31 UTC

Ganhos

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 de fev. de 2025, 11:31 UTC

Ganhos

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4 de fev. de 2025, 11:31 UTC

Ganhos

Merck 4Q Januvia/Janumet Sales $487M >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Keytruda Sales Up 19% >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Keytruda Sales $7.84B >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck Sees FY Rev $64.1B-$65.6B >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Adj EPS $1.72 >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Net $3.74B >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4 de fev. de 2025, 11:30 UTC

Ganhos

Merck 4Q Winrevair Sales $200M >MRK

Comparação entre Pares

Variação de preço

Merck & Co Inc. Previsão

Preço-alvo

By TipRanks

29.19% parte superior

Previsão para 12 meses

Média 111.88 USD  29.19%

Máximo 138 USD

Mínimo 95 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Merck & Co Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

11

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 93.07Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

145 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.